Oliver McCammon
Stock Analyst at LifeSci Capital
(4.88)
# 311
Out of 4,592 analysts
76
Total ratings
49.2%
Success rate
73.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Oliver McCammon
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GLUE Monte Rosa Therapeutics | Maintained: Buy | n/a | $16.05 | - | 14 | Jul 28, 2026 | |
| AURA Aura Biosciences | Maintained: Buy | $23 | $7.02 | +227.64% | 9 | Jul 22, 2026 | |
| CELC Celcuity | Maintained: Buy | $165 | $86.93 | +89.81% | 14 | Jul 15, 2026 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintained: Buy | $38 | $9.07 | +318.96% | 9 | May 26, 2026 | |
| CATX Perspective Therapeutics | Maintained: Buy | $15 | $2.91 | +415.46% | 10 | May 16, 2026 | |
| CADL Candel Therapeutics | Rated: Buy | $16 | $10.04 | +59.36% | 5 | May 16, 2026 | |
| INBX Inhibrx Biosciences | Maintained: Buy | $230 | $83.31 | +176.08% | 3 | May 16, 2026 | |
| JANX Janux Therapeutics | Rated: Buy | $60 | $15.20 | +294.74% | 12 | May 9, 2026 |
Monte Rosa Therapeutics
Jul 28, 2026
Maintained: Buy
Price Target: n/a
Current: $16.05
Upside: -
Aura Biosciences
Jul 22, 2026
Maintained: Buy
Price Target: $23
Current: $7.02
Upside: +227.64%
Celcuity
Jul 15, 2026
Maintained: Buy
Price Target: $165
Current: $86.93
Upside: +89.81%
Corbus Pharmaceuticals Holdings
May 26, 2026
Maintained: Buy
Price Target: $38
Current: $9.07
Upside: +318.96%
Perspective Therapeutics
May 16, 2026
Maintained: Buy
Price Target: $15
Current: $2.91
Upside: +415.46%
Candel Therapeutics
May 16, 2026
Rated: Buy
Price Target: $16
Current: $10.04
Upside: +59.36%
Inhibrx Biosciences
May 16, 2026
Maintained: Buy
Price Target: $230
Current: $83.31
Upside: +176.08%
Janux Therapeutics
May 9, 2026
Rated: Buy
Price Target: $60
Current: $15.20
Upside: +294.74%